Kiniksa Pharmaceuticals (KNSA) to Release Earnings on Tuesday

Kiniksa Pharmaceuticals (NASDAQ:KNSA) is expected to be announcing its earnings results before the market opens on Tuesday, February 25th. Analysts expect the company to announce earnings of ($0.06) per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Kiniksa Pharmaceuticals Trading Up 1.7 %

KNSA stock opened at $20.02 on Monday. The stock has a 50-day moving average price of $19.71 and a two-hundred day moving average price of $22.67. Kiniksa Pharmaceuticals has a 1 year low of $16.56 and a 1 year high of $28.15. The stock has a market cap of $1.45 billion, a PE ratio of -142.99 and a beta of 0.32.

Insiders Place Their Bets

In related news, COO Eben Tessari sold 14,000 shares of the firm’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $19.57, for a total value of $273,980.00. Following the completion of the transaction, the chief operating officer now directly owns 81,975 shares of the company’s stock, valued at approximately $1,604,250.75. This trade represents a 14.59 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Mark Ragosa sold 8,969 shares of the company’s stock in a transaction on Tuesday, December 3rd. The stock was sold at an average price of $21.45, for a total transaction of $192,385.05. Following the sale, the chief financial officer now directly owns 22,958 shares in the company, valued at $492,449.10. This trade represents a 28.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 38,092 shares of company stock valued at $745,589 in the last 90 days. 54.57% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on KNSA shares. Evercore ISI lifted their target price on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. Wedbush reiterated an “outperform” rating and issued a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a report on Monday, January 13th. Finally, JPMorgan Chase & Co. increased their target price on shares of Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $36.60.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.